RLT
RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
Katy MarshallRLT | February 14, 2024
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
Read More
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Amar Kishan, MDRLT | January 24, 2024
Dr. Kishan discusses new research presented at the 2024 PSMA Conference.
Jérémie Calais, MD, PhDRLT | January 24, 2024
The first annual PSMA Conference focused on updates in the field of PSMA-based treatments.
Zachary BessetteRLT | January 19, 2024
Dr. Oliver Sartor presented his high-level “provocateur” thoughts on the optimal time to give PSMA RLT.
Emily MenendezRLT | December 14, 2023
PSA levels were decreased by half in 46.9% of patients, and a decline in CTC count occurred 59.1% of patients.
Zachary BessetteCRPC | December 6, 2023
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Oliver Sartor, MDRLT | December 4, 2023
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Oliver Sartor, MDRLT | December 4, 2023
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Zachary BessetteSUO 2023 | November 22, 2023
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
Michael Morris, MDRoundtable | November 16, 2023
The panel shares insights on future advancements in the field.
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel talks "pearls of wisdom" with radioligand therapy.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration.
Emily MenendezRLT | November 10, 2023
A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was found to be a safe treatment for mCRPC.
Advertisement
Advertisement
Advertisement